Jazz Pharmaceuticals PLC

JAZZ Healthcare Biotechnology

Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 126.0%, free cash flow grew 141.0% and total debt fell 18.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

210.05 4.37 −2.04%
Market cap
$13.9B
P/E
13.8×
Fwd P/E
17.3×
Dividend yield
—
F-score
5/9
Altman Z
1.37
Beneish M
−3.03
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(8.80%) (8.47%) 0.68% 22.11%
Piotroski F-Score
5 5 6 7
ROA
(3.03%) (3.01%) 0.25% 8.54%
ROIC
(4.24%) (3.72%) (0.34%) 8.06%
Return on Tangible Assets
(21.41%) (16.77%) 1.16% 48.26%
Average Days of Receivables
67.10 71.05 68.77 69.88
Free Cash Flow per Share
6.28 5.18 5.07 22.41
Free Cash Flow
380.97 316.14 313.74 1,416.54
Capital Expenditures
(1,010.86) (1,039.64) (1,020.44) (244.54)
Other line items
Cash ROIC
3.35% 2.61% 2.46% 12.48%
Accounts Receivable Turnover
5.59 5.52 5.96 5.77
Accounts Payable Turnover
4.03 5.03 5.44 4.89
Inventory Turnover
0.94 1.12 1.15 1.12
Average Days of Payables
116.12 88.55 68.51 88.01
Days of Inventory on Hand
368.52 302.42 299.72 303.43
Tax Rate
(0.48) (0.43) (1.14) 0.29
Research and Development Expense of Revenue
19.46% 18.34% 17.98% 17.73%
Selling, General and Administrative Expense of Revenue
42.63% 42.40% 37.13% 36.48%
Share Based Compensation of Revenue
6.99% 6.82% 6.71% 6.67%
Interest Coverage
(2.46) (2.21) (0.21) 5.25
Operating CF/Net income
(3.89) (3.81) 45.30 1.77
Depreciation/Fixed assets
3.63 3.48 3.51 3.39
Capex/Depreciation
(1.47) (1.49) (1.43) (0.34)
Revenue per Share
68.50 69.98 71.71 72.81
Operating CF per Share
22.93 22.23 21.55 26.28
Capex per Share
(16.65) (17.05) (16.49) (3.87)
Capex to Sales
0.24 0.24 0.23 0.05

Fold the line items

Columns are period end dates